

1623

PTO/SB/21 (01-03)
Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 09/845,623 TRANSMITTAL Filing Date April 30, 2001 **FORM** First Named Inventor Agrawal **Art Unit** 

(to be used for all correspondence after initial filing)

	Examiner Name			McIntosh, Traviss C.				
Total Number of Pages in This Submission		10	Attorney Docket Number		HYB-004US1	TE(	TECH CENTER 1600/	
ENCLOSURES (Check all that apply)								
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53			<del></del>		After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm or Individual Signature  Date  Wayne A. Keown, Ph.D. (Reg. No. 33,923)  Variable A. Keown, Ph.D. (Reg. No. 33,923)  Date  Wayne A. Keown, Ph.D. (Reg. No. 33,923)								
CERTIFICATE OF TRANSMISSION/MAILING								
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:  3/24/03								
Typed or printed Melanie Legare								
Signature	Signature Mula Leave Date 3/2 4/03							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: HYB-004US1)

Applicant:

Agrawal

**RECEIVED** 

PATE

Serial No.:

09/845,623

APR 0 2 2003

Examiner:

McIntosh III, Traviss C.

TECH CENTER 1600/2900

Filing Date:

30 April 2001

Title:

MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED

IMMUNE STIMULATION BY POSITIONAL MODIFICATION

**OF NUCLEOSIDES** 

Group Art Unit:

1621

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

## **CERTIFICATE UNDER 37 CFR 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

Date of Deposit

Melanie Legare

## **REPLY TO THE OFFICE ACTION MAILED 23 DECEMBER 2002**

Hon. Assistant Commissioner of Patents:

U.S.S.N. 09/845,623 Agrawal et al.

## **Introductory Comments**

This communication is responsive to the Office Action mailed 23 December 2002. Please reconsider the above-identified application in view of the following amendments and remarks.